Step Count and Treatment Response in Neoadjuvant Breast Cancer
Recruiting
Observational Study
Breast Neoplasm Malignant Female
Exercise
Breast Cancer Females
Wearable Technology
Sleep Quality
Smartwatches
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 82 (estimated)
- Sponsor
- Ankara Etlik City Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective multicenter observational study (NEOBRE-STEP) investigates the impact of daily step counts, measured by Huawei Fit 2 smartwatches, on treatment response in patients with non-metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer undergoing neoadjuvant systemic therapy. Patients will wear smartwatches to continuously record step counts, activity intensity…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female patients aged ≥18 years.
* Pathologically confirmed non-metastatic HER2-negative breast cancer.
* Candidates scheduled to receive neoadjuvant systemic therapy followed by surgery.
* ECOG performance status 0-2.
* Ability to provide informed consent.
Exclusion Criteria:…
Contacts